RfD

0.04

0.02

0.004

0.0006

This report

Estimated no-effect level for RBC-AChE inhibition

-

1.0

-

0.24

GB^d

VX^a

27–33% inhibition of RBC-AChE in humans/oral dose

-

2.3 (3 days)

-

0.2-2.0

GB - Grob and Harvey, 1958;

VX-this report

RBC-AChE inhibition in humans/i.v. dose

-

-

1.5-2.0 (30%)

1.0 (50%)

DA, 1974;

Sidell and Groff, 1974

50–60% RBC-AChE inhibition in humans/oral dose

-

10

-

2.4

GB - Grob and Harvey, 1958;

VX-Sidell and Groff, 1974

50% brain ChE inhibition in vitro

1.5 × 10^-8 (c)

0.3 × 10^-8 (c)

-

-

Grob and Harvey, 1958

Acute toxic effects in humans/oral dose

-

20–30

-

2–4.5

GB - Thienes and Haley 1972; Grob and Harvey, 1958;

VX-Sidell and Groff, 1974

human oral LD₅₀ (estimated)

25–50^b

5–20^b

5–20

3–10^b

Somani et al., 1992

rat oral LD₅₀

3700

870–1060 600

400

77–128

DA, 1974 Grob & Harvey, 1958

monkey i.v. LD₅₀

50

20

-

6–11

DA, 1974

rat i.v. LD₅₀

70

45–63

50

6.9–10.1

Dacre, 1984

rat i.p. LD₅₀

490, 800

250

218

-

37–55

DA, 1974

RTECS, 1995